MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, APLS made $268,295K in revenue. $18,348K in net income. Net profit margin of 6.84%.

Income Overview

Revenue
$268,295K
Net Income
$18,348K
Net Profit Margin
6.84%
EPS
$0.15
Unit: Thousand (K) dollars
Revenue Breakdown
    • Syfovre
    • Licensing And Other Revenue
    • Empaveli Pegcetacoplan

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
268,295 199,913 458,578 178,494
Cost of sales
40,547 29,719 24,531 13,626
Research and development
76,958 74,233 68,186 67,015
Selling, general and administrative
124,323 147,103 142,678 131,139
Total operating expenses
241,828 251,055 235,395 211,780
Net operating income/(gain)
26,467 -51,142 223,183 -33,286
Interest income
2,914 3,502 4,376 2,607
Interest expense
10,317 10,847 11,279 11,152
Other income/(expense), net
88 -151 37 146
Net income/(gain) before taxes
19,152 -58,638 216,317 -41,685
Income tax expense
496 313 602 466
Net income/(gain)
18,656 -58,951 215,715 -42,151
Unrealized loss/(gain) on pension plans
-30 -137 -
Foreign currency translation
-308 327 32 485
Total other comprehensive income/(loss)
-308 297 169 485
Comprehensive income/(gain), net of tax
18,348 -58,654 215,884 -41,666
Basic EPS
0.15 -0.463 1.71 -0.33
Diluted EPS
0.15 -0.425 1.67 -0.33
Basic Average Shares
127,682,000 126,679,000 126,424,000 126,024,000
Diluted Average Shares
131,424,000 137,876,000 130,067,000 126,024,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Syfovre$150,719K (15.78%↑ Y/Y)Empaveli Pegcetacoplan$41,291K (109.32%↑ Y/Y)Product$192,010K (28.09%↑ Y/Y)Licensing And OtherRevenue$76,285K (351.47%↑ Y/Y)Revenue$268,295K (60.85%↑ Y/Y)Net operatingincome/(gain)$26,467K (131.76%↑ Y/Y)Interest income$2,914K (9.63%↑ Y/Y)Otherincome/(expense), net$88K (153.33%↑ Y/Y)Total operatingexpenses$241,828K (-3.32%↓ Y/Y)Net income/(gain)before taxes$19,152K (120.84%↑ Y/Y)Interest expense$10,317K (-6.63%↓ Y/Y)Selling, general andadministrative$124,323K (-3.88%↓ Y/Y)Research and development$76,958K (-10.95%↓ Y/Y)Cost of sales$40,547K (18.01%↑ Y/Y)Net income/(gain)$18,656K (120.23%↑ Y/Y)Income tax expense$496K (45.45%↑ Y/Y)Comprehensive income/(gain),net of tax$18,348K (119.95%↑ Y/Y)Total othercomprehensive income/(loss)-$308K (-221.26%↓ Y/Y)Foreign currencytranslation-$308K (-221.26%↓ Y/Y)

APLS_BIG copy-svg

Apellis Pharmaceuticals, Inc. (APLS)

APLS_BIG copy-svg

Apellis Pharmaceuticals, Inc. (APLS)